Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
volrustomig + casdatifan
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
volrustomig + casdatifan is an investigational combination therapy for advanced clear cell renal cell carcinoma (ccRCC). Volrustomig is a bispecific monoclonal antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), designed to enhance anti-tumor immune response. Casdatifan is a small molecule inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α), intended to disrupt hypoxia signaling that drives renal cancer growth. In combination, these mechanisms are being evaluated for additive or synergistic effects in frontline kidney cancer treatment. The combination is currently under clinical investigation in a multicenter, randomized Phase Ib/III study.[1][2][4][5][7][8]
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)EPAS1 (Hypoxia-inducible factor 2-alpha)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on volrustomig + casdatifan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on volrustomig + casdatifan.